Therapy Area topics
Cardiovascular
PCSK9 pipeline shows signs of saturation
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
Central Nervous System
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Lecanemab can; now the wait for details begins
Eisai is rewarded for doubling down on lecanemab with an apparent win that endorses 20 years of research.
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
Diabetes
EASD 2022 – Pfizer’s oral GLP-1s struggle for a therapeutic window
Neither project is an obvious candidate for phase 3, so more mid-stage trials are planned.
Akero’s imperfect Harmony
An apparent hit in Nash has more than doubled the group’s market cap. But are the data all they seem?
Digital Health
ESC 2022 – Preventicus gets halfway there
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
Better Therapeutics banks on data and partnerships
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Trad device start-ups catch the cash
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
Oncology
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
Various
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
